




## Oncodriver inhibition and CD4<sup>+</sup> Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2<sup>+</sup> and triple negative breast cancer: implications for combining immune and targeted therapies


### SUPPLEMENTARY MATERIALS




**Supplementary Figure 1: Combined HER2 and HER3 blockade enhances Th1 cytokine-induced senescence and apoptosis in MCF-7 breast cancer cells.** (A) MCF-7 cells transfected with non-target (NT), HER2, HER3, or both HER2 and HER3 siRNA, and then treated with TNF- $\alpha$  and IFN- $\gamma$ . *Left panel*: densitometric analysis presented as % of SA- $\beta$ -gal-positive cells, mean  $\pm$  SD ( $n = 3$ ), \*\*\* $p < 0.001$ . *Right panel*: representative data from 1 of 3 independent experiments. (B) MCF-7 cells transfected with NT, HER2, HER3, or both HER2 and HER3 siRNA probed with HER2 and HER3 specific antibodies. (C) Expressions of p15INK4b and cleaved caspase-3 proteins in cells described in A were analyzed by western blot. Vinculin was used as loading control. Similar results were observed in 3 independent experiments. KD denotes knocked down.




**Supplementary Figure 2: Effect of Th1 cytokines on senescence and apoptosis.** (A) SK-BR-3 cells were co-cultured with CD4<sup>+</sup> T-cells alone (CD4<sup>+</sup> only, 1), CD4<sup>+</sup> T-cells + mature type 1 dendritic cells (DC, 4-7) or immature DC (IDC, 2-3) pulsed with HER2 peptide (H, 2, 5, 6, 7) or irrelevant peptide (BRAF, B, 3, 4). Compared with an IgG isotype control, senescence induced in SK-BR-3 treated with CD4<sup>+</sup>/DC H is partially rescued by neutralizing TNF- $\alpha$  and IFN- $\gamma$  with specific antibodies (75.27 % rescue). *Left panel:* densitometric analysis presented as % of SA- $\beta$ -gal-positive cells, mean  $\pm$  SD ( $n = 3$ ), \*\*\* $p < 0.001$ . *Right panel:* Representative data from 1 of 3 independent experiments. (B) Increased p15INK4b and cleaved caspase-3 expressions suggest induced senescence and apoptosis, respectively, when co-cultured with DC H/CD4<sup>+</sup> T-cells, but not DC B, IDC H, and IDC B groups. Compared with IgG isotype control, senescence and apoptosis induced in SK-BR-3 treated with CD4<sup>+</sup>/DC H were partially rescued by neutralizing TNF- $\alpha$  and IFN- $\gamma$  with specific antibodies. Vinculin was used as loading control. Results are representative of 3 experiments.




**Supplementary Figure 3: Effect of trastuzumab and pertuzumab on AKT activation by heregulin in breast cancer cell lines.** Serum-starved T-47D, HCC-1419 and JIMT-1 cells were treated with trastuzumab and pertuzumab for one hour and stimulated with HRG (five minutes). Cell extracts were subjected to western blot analysis using specific anti-phospho-AKT serine 473 antibody. Vinculin was used as loading control. Similar results were observed in 3 independent experiments.




**Supplementary Figure 4: Th1 cytokines TNF- $\alpha$  and IFN- $\gamma$  synergize to induce senescence and apoptosis in trastuzumab and pertuzumab resistant breast cancer cells.** (A) HCC-1419 and JIMT-1 cells were untreated, or incubated with increasing concentrations of TNF- $\alpha$  and IFN- $\gamma$ : 5 ng/ml and 50 U/ml, 10 ng/ml and 100 U/ml, 50 ng/ml and 500 U/ml, 75 ng/ml and 750 U/ml, 100 ng/ml and 1000 U/ml. *Left panel*, densitometric analysis presented as % of SA- $\beta$ -gal-positive cells, mean  $\pm$  SD ( $n = 3$ ), \*\*\* $p < 0.001$ . *Right panel*: representative data from 1 of 3 independent experiments in HCC-1419 cells (*top panel*) and JIMT-1 cells (*bottom panel*). (B and C) p15INK4b and cleaved caspase-3 expression of HCC-1419 (B) and JIMT-1 (C) cells described in A. Vinculin was used as loading control. Similar results were observed in 3 independent experiments.



**Supplementary Figure 5: Th1-mediated Stat1 activation and HER2 and HER3 blockade enhances Th1-mediated Stat1 activation.** T-47D cells were transfected with non-target (NT), HER2, HER3 or HER2/HER3 siRNA, the cells were serum starved for 48 hours and untreated or treated with 100 ng/ml TNF- $\alpha$  and 1000 U/ml IFN- $\gamma$  for 5 min. HER2 and HER3 expression, phospho-Stat1 tyrosine 701, phospho-Stat1 serine 727, phospho-Stat3 tyr 705 and phospho-p38 MAPK threonine 180/ tyrosine 182 were determined by western blot. Vinculin was used as loading control. Similar results were observed in 3 independent experiments. KD denotes knocked down.



**Supplementary Figure 6: Combined EGFR and HER3 blockade sensitizes Th1 cytokine resistant triple negative breast cancer cells to senescence and apoptosis induction.** (A) Densitometric analysis presented as % of SA-β-gal-positive MDA-MB-468 cells transfected with non-target (NT) or EGFR and HER3 siRNA, untreated or treated with 200 ng/ml TNF-α (T) and 2000 U/ml IFN-γ (I), mean ± SD ( $n = 3$ ), \*\* $p < 0.01$ , \*\*\* $p < 0.001$ . *Inset:* MDA-MB-468 cells transfected with non-target (NT) or EGFR and HER3 siRNA probed with EGFR and HER3 specific antibodies. Vinculin was used as loading control. (B) p15INKb or cleaved caspase-3 expression of cells described in A. Vinculin was used as loading control. Similar results were observed in 3 independent experiments. (C) MDA-MB-468 cells were transfected with non-target (NT) or EGFR and HER3 siRNA, untreated or treated with 200 ng/ml TNF-α and 2000 U/ml IFN-γ for 5 min. EGFR and HER3 expression, phospho-Stat1 serine 727 and phospho-p38 MAPK threonine 180/ tyrosine 182 were determined by western blot. Vinculin was used as loading control. Similar results were observed in 3 independent experiments. (D) Expression of phospho-Stat1 tyrosine 701 was detected in MDA-MB-468 cells treated with 200 ng/ml cetuximab for 48 hours followed by 200 ng/ml TNF-α and 2000 U/ml IFN-γ for 5 minutes. β-actin was used as loading control. Similar results were observed in 3 sets of independent experiments. KD denotes knocked down.



**Supplementary Figure 7: TNBC cells are sensitive to Th1 cytokine treatment.** MDA-MB-231 cells were treated with 200 ng/ml cetuximab for 48 hours followed by 200 ng/ml TNF- $\alpha$  and 2000 U/ml IFN- $\gamma$  for 5 minutes. Expression of EGFR, HER2, phospho-Stat1 tyrosine 701 and phospho-Stat3 tyrosine 705 were determined by Western blotting.  $\beta$ -actin was used as loading control. Similar results were observed in 3 sets of independent experiments.